Total Syntheses and Structural Reassignment of Ugonin T and Neougonin B: Anti-inflammatory Flavonoids Related to Helminthostachys zeylanica Authors: Yuh-Chiang Shen, Chang-Hui Chen, San-Yao Su, Yi-Jyung Lin, Zhong-You Lai, Cheng-Ming Chen, Chun-Wei Chen, Fei-Pei Kao, Ming-Jaw Don, Yea-Hwey Wang Published: 2026 ABSTRACT This study reports the first total syntheses of the naturally occurring flavonoids ugonin C (1), ugonin F (2), and, based on the originally proposed structures, compounds 3 and 4 (corresponding to the structures first assigned to ugonin T and neougonin B, respectively), all featuring a dihydrofuran ring fused to a phenolic moiety. In addition, a series of analogues (18, 19, 22, 23a, 23b, 27a, 27b, and 28) were synthesized to explore their biological activities. On the basis of synthetic strategy and detailed NMR analyses, the structures of naturally occurring ugonin T and neougonin B were reassigned to correspond to compounds 23a and 19, respectively. Biological evaluation revealed that several synthesized compounds exhibited potent anti-inflammatory activity, particularly compound 27a, which showed the strongest inhibition of NF-κB associated nitric oxide production in BV2 microglial cells. The rhizomes of Helminthostachys zeylanica (L.) Hook. (Ophioglossaceae), also known as “Daodi-Ugon”, are used in traditional Chinese medicine as an antipyretic and antiphlogistic agent. Ugonins C (1), F (2), T (originally proposed as 3), and neougonin B (originally proposed as 4) were isolated and characterized as four minor components from H. zeylanica. − (Figure ). These natural products 1–4 possess a flavonoid skeleton, and a dihydrofuran ring is connected to the phenolic moiety. Compound 3 showed anti-inflammatory activity. Until recently, total syntheses of other ugonins from this plant, including ugonstilbenes A–C and ugonins L, S, U, and Z, had been reported; , however, no total syntheses of 1–4 had previously been reported. Naturally occurring flavonoids and synthesized analogues have been reported to have various biological activities including antioxidant, , anti-inflammatory, ,− antibacterial, and cytotoxic effects. ,,, They have potential as novel therapeutic agents. This study aimed to synthesize ugonins C, F, T, and neougonin B in order to further study their biological activities. The structures of 1–4 were determined on the basis of their NMR spectral data. − In addition, analogues 18, 19, 22, 23a, 23b, 27a, 27b, and 28 were also synthesized. The synthesized compounds were evaluated for their anti-inflammatory and antioxidant activities. Chemical structures of ugonin C (1) and ugonin F (2) (left), and the originally proposed structures for ugonin T (3) and neougonin B (4) (right). Results and Disscussion Retrosynthetic Analysis The retrosynthetic analysis for ugonins C (1) and F (2) is shown in Scheme . Ugonin F could be obtained from ugonin C by demethylation with boron tribromide (BBr3) in dichloromethane (CH2Cl2). − The flavone skeleton of ugonin C could be synthesized via β-diketone intermediate, which was prepared from 10a and methyl benzoate 15b. ,, Methyl benzoate 15b could be prepared from commercially available 4-hydroxybenzoic acid via benzylation with benzyl bromide (BnBr) and followed by esterification with MeOH in the presence of acid. Compound 10a could be obtained from 9a by microwave irradiation reaction. Compound 9a could be obtained from 8a by prenylation with prenyl bromide. Compound 8a could be obtained from 7a in the presence of 3 N HCl in MeOH under reflux. Compound 7a could be obtained from 5a via protection of hydroxy groups with chloromethyl methyl ether (MOMCl) and followed by benzylation with BnBr. , Compound 5a could be obtained by acylation from commercially available 1,3,5-trihydoxybenzene with methoxyacetyl chloride in the presence of aluminum chloride (AlCl3). Compounds 3 and 4, previously assigned as ugonin T (3) and neougonin B (4), could be obtained using a methodology similar to that of ugonins C and F. Retrosynthetic Analysis Synthesis of Intermediates 10a, 10b, 12a, and 12b Treatment of 1,3,5-trihydroxybenzene with methoxyacetyl chloride in the presence of AlCl3 in CH2Cl2 and diethyl ether (Et2O) gave 5a according to the literature method. Compound 5a and 2′,4′,6′-trihydoxyacetophenone (5b) as starting materials reacted with MOMCl in the presence of N,N-diisopropylethylamine (DIPEA) in CH2Cl2 to yield 6a and 6b, which were converted to 7a and 7b by benzylation with BnBr, respectively. , Treatment of 7a and 7b with 3 N HCl in MeOH, followed by prenylation with prenyl bromide according to reported procedures, , gave 9a and 9b, respectively. Compounds 9a and 9b in N-methylformamide (NMF) and H2O were heated under microwave irradiation (250 W, 220 °C) to produce 10a and 10b in moderate yield, respectively. Methylation of 10a and 10b with MeI in N,N-dimethylformamide (DMF) yielded 11a and 11b, which were converted to 12a and 12b by hydrogenation in the presence of 10% palladium on activated carbon (Pd/C) catalyst in good yield, respectively (Scheme ). Synthesis of Intermediates 10a, 10b, 12a and 12b Preparation of 13a, 13b, 15a, 15b, 15c, and 15d Commercially available 3,4-bis­(benzoyloxy)­benzaldehyde was oxidized by potassium permanganate (KMnO4) in acetone and H2O to give 13a in good yield. 4-Hydroxybenzoic acid was benzylated with BnBr to produce 13b. Esterification of 3,4-dihydroxybenzoic acid and 4-hydroxybenzoic acid with MeOH in the presence of 3 N HCl gave the corresponding methyl ester 14a and 14b, respectively. Compounds 13a and 13b were then converted to 15a and 15b by esterification with MeOH in the presence of acid, respectively. Treatment of 14a and 14b with tert-butyldimethylsilyl chloride (TBDMS-Cl) in the presence of DIPEA in CH2Cl2 provided 15c and 15d, respectively (Scheme ). Preparation of 13a, 13b, 15a, 15b, 15c, and 15d Synthesis of Ugonin C (1), Ugonin F (2), 18, and 19 Following the literature method, treatment of 10a with lithium bis­(trimethylsilyl)­amide (LiHMDS) in THF at −78 °C generated the lithium enolate of a ketone, which underwent reaction with methyl benzoate 15a and 15b, following literature procedures, ,, providing β-diketone intermediates 16a and 16b, respectively, which were used in the next step without purification. Treatment of 16a and 16b with glacial acetic acid (AcOH) and a few drops concentrated sulfuric acid (H2SO4) at 100 °C for 1 h yielded 3-methoxyflavones 17a and 17b, respectively. Hydrogenation of 17a and 17b in the presence of Pd/C catalyst in EtOAc gave 18 and ugonin C (1), respectively. Compounds 18 and 1 were demethylated with excess BBr3 in CH2Cl2, following a literature procedure, − to afford 19 and ugonin F (2), respectively (Scheme ). Synthesis of Ugonin C (1), Ugonin F (2), 18, and 19 Synthesis of 3, 22, 23a, and 23b Following the literature method, treatment of 12b with LiHMDS in THF at −78 °C generated the lithium enolate of a ketone, which underwent reaction with methyl benzoate 15c and 15d, providing a β-diketone intermediates 20a and 20b, respectively, ,, which were used in the next step without purification. Compounds 20a and 20b were then reacted with AcOH and a few drops conc. H2SO4 at 100 °C for 1 h, followed by treatment with tetrabutylammonium fluoride (TBAF) in THF yielded 21a and 21b, respectively. , Demethylation of 21a and 21b with 1.4 eq. BBr3 in CH2Cl2 following the same literature procedure, − gave 3 and 22, respectively. With a similar fashion, starting from 10b and 15c or 15d, we were able to obtain the analogues 23a and 23b, respectively (Scheme ). Synthesis of 3, 22, 23a, and 23b Synthesis of 4, 27a, 27b, and 28 Coupling of 12a with 13a and 13b, following a literature procedure, , gave 24a and 24b in the presence of 1-ethyl-3-(3-(dimethylamino)­propyl)­carbodiimide (EDCI) and 4-dimethylaminopyridine (DMAP) in CH2Cl2 in good yield, respectively. Treatment of 24a and 24b with 1.0 M LiHMDS in THF at −20 °C providing a β-diketone intermediates which were used in the next step without purification. β-Diketone intermediates were then reacted with AcOH and a few drops conc. H2SO4 at 100 °C for 1 h to yield products 25a and 25b, respectively. Hydrogenation of 25a and 25b in the presence of Pd/C catalyst in THF/MeOH (1:1) provided 26a and 26b, respectively. Partial demethylation of 26a and 26b with 1.2 eq BBr3 in CH2Cl2 gave 27a and 27b, respectively. Compounds 27a and 27b were demethylated with excess BBr3 in CH2Cl2 to afford 4 and 28, respectively (Scheme ). Synthesis of 4, 27a, 27b, and 28 Structural Reassignment of Ugonin T and Neougonin B The NMR data of synthesized compounds 1 and 2 in acetone-d 6 were summarized in Table . The NMR data of synthesized compound 2 was consistent with that of reported naturally occurring ugonin F. The NMR data of reported ugonin T, neougonin B, synthesized compounds 3, 4, 19, and 23a in CD3OD were summarized in Tables and . The 1H NMR results indicated that the structure of the synthesized compound 23a was more than likely to be consistent with that of reported naturally occurring ugonin T, showing a singlet proton signal at C-6 (δH 6.18). The structure of the synthesized compound 19 was more than likely to be consistent with that of reported naturally occurring neougonin B, showing a singlet proton signal at C-6 (δH 6.15). In addition, in the HMBC spectrum (acetone-d 6) of 19, a hydroxy group at C-5 (δH 12.5) showed correlations with C-4a (δC 104.7, C), C-5 (δC 162.8, C), and C-6 (δC 94.3, CH) (Figure S109). It was indicated that the dihydrofuran ring should be located at C-7/C-8 positions like ugonins C and F instead of located at C-6/C-7 positions. Taken together, the synthetic and spectroscopic data strongly support reassignment of naturally occurring ugonin T and neougonin B to compounds 23a and 19, respectively. 1 1H and 13C NMR Data of Reported Naturally Occurring Ugonin F, Synthesized Compounds 1, and 2 in Acetone-d 6 reported ugonin F3 12positionδH δC δH δC δH δC 2-146.8-156.7-146.83-136.5-139.0-136.54-176.8-179.7-176.84a-104.8-106.5-104.85-162.8-163.7-162.966.18 (s)94.96.17 (s)94.66.19 (s)94.47-165.9-165.8-165.98-113.5-113.5-113.68a-152.9-152.9-152.99-44.4-44.4-44.4104.56 (q, 7.0)91.44.55 (q, 6.6)91.44.57 (q, 6.6)91.4111.40 (d, 7.0)14.41.39 (d, 6.6)14.31.41 (d, 6.6)14.412 1.33 (s)21.71.29 (s)21.81.33 (s)21.713 1.60 (s)26.21.56 (s)26.21.61 (s)26.21′-123.4-122.5-123.42′,6′8.12 (d, 8.5)130.38.00 (d, 9.0)131.08.14 (d, 9.0)130.33′,5′7.04 (d, 8.5)116.37.05 (d, 9.0)116.57.05 (d, 9.0)116.54′-160.2-161.1-160.23-OMe--3.85 (s)60.3--5-OH12.4 (s)-13.1 (s)-12.5 (s)-a(Multiplicity, J in Hz) in ppm.bInterchangeable. 1H and 13C NMR Data of Reported Naturally Occurring Ugonin F, Synthesized Compounds 1, and 2 in Acetone-d 6 (Multiplicity, J in Hz) in ppm. Interchangeable. 2 1H and 13C NMR Data of Reported Naturally Occurring Ugonin T and Synthesized Compounds 3 and 23a in CD3OD reported ugonin T4 3 23a positionδH δC δH δC δH δC 2-166.2-166.2-166.136.55 (s)104.46.55 (s)103.96.54 (s)104.24-184.1-184.3-183.94a-106.2-106.6-106.15-154.5-158.2-163.86-114.7-119.26.18 (s)95.47-166.8-166.5-166.786.18 (s)95.56.41 (s)90.4-114.58a-163.9-159.3-154.49-45.1-44.5-44.9104.56 (q, 6.5)92.24.49 (q, 6.5)92.24.55 (q, 6.5)92.1111.42 (d, 6.5)14.71.37 (d, 6.5)14.61.41 (d, 6.5)14.512 1.34 (s)22.11.23 (s)20.91.34 (s)21.913 1.62 (s)26.71.47 (s)25.51.61 (s)26.51′-123.9-123.6-123.82′7.39 (d, 1.8)114.37.35 (d, 2.4)114.17.39 (d, 2.0)114.13′-147.4-147.0-147.24′-151.2-151.0-151.15′6.92 (d, 8.3)117.06.88 (d, 7.8)116.86.92 (d, 8.0)116.96′7.36 (dd, 8.3, 1.8)120.47.36 (dd, 7.8, 2.4)120.37.37 (dd, 8.0, 2.0)120.2a(Multiplicity, J in Hz) in ppm.bInterchangeable. 1H and 13C NMR Data of Reported Naturally Occurring Ugonin T and Synthesized Compounds 3 and 23a in CD3OD (Multiplicity, J in Hz) in ppm. Interchangeable. 3 1H and 13C NMR Data of Reported Naturally Occurring Neougonin B and Synthesized Compounds 4 and 19 in CD3OD reported neougonin B5 419positionδH δC δH δC δH δC 2-147.9-147.9-147.83-137.4-137.2-137.24-177.7-177.6-177.64a-105.5-105.7-105.35-153.4-157.3-163.16-114.2-118.36.15 (s)94.67-166.4-166.3-166.286.17 (s)94.76.36 (s)89.9-113.98a-163.3-158.1-153.39-45.0-44.4-44.8104.55 (q, 6.6)92.14.47 (d, 6.6)92.14.52 (q, 6.6)92.0111.13 (d, 6.6)19.71.36 (d, 6.6)14.61.40 (d, 6.6)14.512 1.30 (s)22.01.23 (s)20.91.32 (s)21.813 1.61 (s)26.61.47 (s)25.51.59 (s)26.51′-124.3-124.1-124.22′7.75 (d, 1.8)116.17.72 (d, 1.8)116.07.73 (d, 1.8)116.03′-146.5-146.2-146.44′-149.0-148.8-148.95′6.90 (d, 8.4)116.46.87 (d, 8.4)116.26.89 (d, 8.4)116.36′7.62 (dd, 8.4, 1.8)121.67.62 (dd, 8.4, 1.8)121.67.61 (dd, 8.4, 1.8)121.5a(Multiplicity, J in Hz) in ppm.bInterchangeable. 1H and 13C NMR Data of Reported Naturally Occurring Neougonin B and Synthesized Compounds 4 and 19 in CD3OD (Multiplicity, J in Hz) in ppm. Interchangeable. It is noteworthy that the reported melting point of natural ugonin T (202–204 °C) differs considerably from that of synthesized 3 (258–260 °C) and its regioisomer 23a (251–252 °C) alike, and the reported melting point of natural ugonin C (236–237 °C) likewise differs from that of synthesized 1 (229–231 °C). No melting point or IR data have been reported for natural neougonin B. These discrepancies most likely reflect impurity or partial decomposition of the small quantities of natural material originally isolated, rather than a structural difference; melting point and IR are therefore not reliable criteria for distinguishing among these closely related regioisomers. In contrast, the full 1H and 13C NMR data, including the diagnostic C-6 chemical shifts and HMBC correlations described above, unambiguously distinguish the regiochemistry and provide the basis for the structural reassignment reported here. The inhibitory effects of synthesized compounds 1–4, 18, 19, 22, 23a, 23b, 27a, 27b, and 28 on nitric oxide (NO) production were evaluated in BV2 microglial cells, as shown in Table . PDTC (pyrrolidine dithiocarbamate), an NF-κB inhibitor, was used as the positive control. The half-maximal effective concentration (EC50) for NO inhibition was determined based on nitrite accumulation in the culture medium. No obvious cytotoxicity was observed under the tested condition, indicating that the observed NO inhibitory effects were not attributable to cytotoxicity. As summarized in Table , most synthesized compounds exhibited potent NO inhibitory activity, with several compounds outperforming the positive control PDTC (EC50 = 12.1 μg/mL). Notably, compounds 3, 4, and 27a demonstrated the strongest activity, with EC50 values ranging from 1.81 to 2.38 μg/mL, whereas the remaining compounds showed moderate activity (EC50 = 3.23–9.47 μg/mL). Structure–activity relationship analysis suggested that the position of the dihydrofuran ring is critical for anti-inflammatory activity, with substitution at C-6/C-7 positions significantly enhancing NO inhibitory potency. In addition, the presence of dihydroxy groups on the B-ring further contributed to the observed activity, highlighting their importance in modulating anti-inflammatory effects. Notably, compound 27a demonstrated the strongest inhibition of nitric oxide production in BV-2 microglial cells, which may be associated with suppression of NF-κB activation and subsequent downregulation of iNOS expression (Figure ). 4Inhibitory Effects of Synthesized Compounds 1–4, 18, 19, 22, 23a, 23b, 27a, 27b, and 28 in Nitric Oxide Production in Microglia Cell Line (BV2) compoundsEC50 (μg/mL)compoundsEC50 (μg/mL) 1 9.47 ± 0.32 22 12.8 ± 2.24 2 5.49 ± 1.01 23a 3.23 ± 0.80 3 2.38 ± 0.99 23b 3.36 ± 0.70 4 2.04 ± 0.41 27a 1.81 ± 0.20 18 3.46 ± 0.36 27b 4.04 ± 0.22 19 3.47 ± 0.76 28 3.62 ± 0.64PDTC12.1 ± 0.28 aResults are expressed as the mean ± S.E.M. from three independent experiments, each performed in triplicate. E50 represented the 50% effective concentration to inhibit NO production. Pyrrolidine dithiocarbamate (PDTC), an established inhibitor of NF-κB signaling, was used as a mechanistic positive control associated with NF-κB-mediated NO production. Inhibitory Effects of Synthesized Compounds 1–4, 18, 19, 22, 23a, 23b, 27a, 27b, and 28 in Nitric Oxide Production in Microglia Cell Line (BV2) Results are expressed as the mean ± S.E.M. from three independent experiments, each performed in triplicate. E50 represented the 50% effective concentration to inhibit NO production. Pyrrolidine dithiocarbamate (PDTC), an established inhibitor of NF-κB signaling, was used as a mechanistic positive control associated with NF-κB-mediated NO production. Compound 27a suppresses LPS-induced NF-κB (pP65) activation and iNOS expression in BV-2 cells. Upper panels: BV-2 cells were treated with vehicle alone (Control), LPS plus saline, or pretreated with compound 27a (0.5, 1.0, or 1.5 μM) for 3 h followed by LPS stimulation (1 μg/mL) for 4 h. A compound 27a-alone group (1.0 μM only) was included as an additional control. Representative confocal images show DAPI (blue), iNOS (green), and pP65 (red) staining. Arrows indicate pP65/iNOS double-positive cells. Images were obtained using a Carl Zeiss LSM 780 confocal microscope at 60× magnification. Scale bar = 20 μm. Lower panel: quantitative analysis of pP65/iNOS double-positive cells (%). Data are shown as the mean ± S.E.M. (n = 3). *P < 0.05 compared with the LPS + saline group. Additionally, the antioxidant potential of synthesized compounds was assessed using the DPPH radical scavenging assay. Based on the DPPH radical scavenging assay (Table ), distinct structure–activity relationships (SAR) could be identified among the synthesized flavonoid derivatives. First, compounds bearing catechol-type dihydroxy substitution on the B-ring (3′,4′-dihydroxy) exhibited significantly enhanced radical scavenging activity. For instance, compounds 4 (EC50 = 7.72 μg/mL), 18 (9.75 μg/mL), and 19 (7.20 μg/mL) demonstrated stronger antioxidant effects compared to mono-hydroxylated analogues such as 1, 2, 22, 23b, and 27b (EC50 > 50 μg/mL). This observation suggests that the ortho-dihydroxy (catechol) moiety plays a critical role in stabilizing DPPH radicals. The position of the dihydrofuran ring appears to exert a modulatory but less dominant effect compared to B-ring substitution. Compounds with similar catechol substitution but different ring fusion patterns (e.g., 3, 23a, and 27a) still retained moderate to strong activity, suggesting that electronic properties of the phenolic B-ring appear to be a major determinant, while the fused dihydrofuran system may influence activity through conformational or steric effects. 5Inhibitory Effects of Synthesized Compounds 1–4, 18, 19, 22, 23a, 23b, 27a, 27b, and 28 in DPPH Free Radical Scavenging Activity compoundsEC50 (μg/mL)compoundsEC50 (μg/mL) 1 >50 22 >50 2 >50 23a 11.8 ± 0.20 3 12.1 ± 0.34 23b >50 4 7.72 ± 1.56 27a 10.4 ± 0.38 18 9.75 ± 0.40 27b >50 19 7.20 ± 1.49 28 22.3 ± 0.03Trolox (μM)16.3 ± 0.01 aResults are presented as the mean ± SE of three independent experiments. EC50 is defined as the concentration required to achieve 50% scavenging of DPPH radicals. Trolox (μM) was included as a positive control. Inhibitory Effects of Synthesized Compounds 1–4, 18, 19, 22, 23a, 23b, 27a, 27b, and 28 in DPPH Free Radical Scavenging Activity Results are presented as the mean ± SE of three independent experiments. EC50 is defined as the concentration required to achieve 50% scavenging of DPPH radicals. Trolox (μM) was included as a positive control. In summary, a series of 12 flavonoids bearing a dihydrofuran ring at different positions were successfully synthesized. Based on comprehensive NMR analysis, the structures of compounds 23a and 19 were confirmed to correspond to the naturally occurring ugonin T and neougonin B, respectively. Among the synthesized compounds, 27a exhibited the most potent anti-inflammatory activity, highlighting the importance of specific structural features in modulating biological effects. These findings provide valuable insights into the structure–activity relationships of this class of flavonoids and suggest that compound 27a represents a promising lead for further development in the treatment of inflammation-related neurological disorders. Experimental Section General Experimental Procedures Melting points were measured on a Yanaco MP-S9 micro melting point apparatus, and the thermometer was used without correction. IR spectra were obtained on a Nicolet Avatar 320 FTIR spectrophotometer. Nuclear magnetic resonance spectra were recorded on Varian VNMRS 600 MHz and Unity Inova 500 MHz FT-NMR spectrometers. Chemical shifts are reported in parts per million (δ) units relative to internal deuterium solvent. The high-resolution ESIMS spectra were measured on a Thermo Scientific Q Exactive Focus Orbitrap mass spectrometer. Microwave irradiation was performed on CEM Discover apparatus. Column chromatography was performed with E. Merck 230–400 mesh silica gel. 1-(6-(Benzyloxy)-4-hydroxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)-2-methoxyethan-1-one (10a) To a mixture of 9a (1.78 g, 5.0 mmol) in NMF (15 mL) and H2O (1 mL) was subjected to microwave irradiation (250 W and 220 °C) with a cooling condenser for 1 h. After cooling, the reaction mixture was purified by column chromatography eluting with 5% EtOAc in n-hexane to yield 10a (0.71 g, 40%) as a white solid: mp 109–111 °C; IR (KBr) νmax 2962, 2886, 1611, 1459, 1439, 1382, 1260, 1230, 1200, 1117, 1062, 968, 916, 867, 838, 760, 702, cm–1; 1H NMR (600 MHz, CDCl3): δ 1.18 (s, 3H), 1.34 (d, J = 6.6 Hz, 3H), 1.41 (s, 3H), 3.32 (s, 3H), 4.44 (q, J = 6.6 Hz, 1H), 5.03 (s, 2H), 5.94 (s, 1H), 7.32–7.41 (m, 5H), 13.6 (s, OH); 13C NMR (150 MHz, CDCl3): δ 14.3, 20.5, 25.4, 29.7, 43.6, 59.1, 71.4, 78.5, 86.7, 91.2, 104.8, 114.7, 128.1 (2C), 128.7, 128.8 (2C), 135.3, 162.5, 162.8, 165.8, 201.0; HRESIMS m/z 379.1507 [M + Na]+ (calcd for C21H24O8Na, 379.1516). 1-(6-(Benzyloxy)-4-hydroxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)-ethan-1-one (10b) Compound 10b was prepared from 9b using the same procedure as for 10a, and was obtained in 36% yield as a white solid: mp 91–92 °C; IR (KBr) νmax 3115, 3086, 3037, 2925, 1601, 1430, 1388, 1261, 1183, 1112, 1061, 977, 866, 819, 745 cm–1; 1H NMR (600 MHz, CDCl3): δ 1.18 (s, 3H), 1.34 (d, J = 6.6 Hz, 3H), 1.41 (s, 3H), 2.51 (s, 3H), 4.42 (q, J = 6.6 Hz, 1H), 5.04 (s, 2H), 5.95 (s, 1H), 7.32–7.39 (m, 5H), 14.0 (s, OH); 13C NMR (150 MHz, CDCl3): δ 14.3, 20.5, 25.4, 33.5, 43.5, 71.1, 86.8, 91.0, 106.6, 114.2, 127.9 (2C), 128.4, 128.7 (2C), 135.7, 162.6, 163.0, 165.4, 203.4; HRESIMS m/z 325.1454 [M – H]− (calcd for C20H21O4, 325.1434). 1-(6-(Benzyloxy)-4-methoxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)-2-methoxyethan-1-one (11a) To a mixture of 10a (1.21 g, 3.40 mmol) in DMF (100 mL) was added K2CO3 (0.97 g, 7.03 mmol) and MeI (0.6 mL, 9.64 mmol), and the reaction mixture was refluxed for overnight. After cooling, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude residue was then added water and extracted with EtOAc three times. The combined EtOAc layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography eluting with 5% acetone in n-hexane to give 11a (1.16 g, 91%) as a colorless oil: IR (neat) νmax 3066, 3036, 2982, 2935, 2829, 1719, 1611, 1480, 1458, 1420, 1383, 1307, 1220, 1168, 1104, 1060, 924, 869, 815, 741, 701 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.13 (s, 3H), 1.31 (d, J = 6.6 Hz, 3H), 1.37 (s, 3H), 3.35 (s, 3H), 3.77 (s, 3H), 4.32 (q, J = 6.6 Hz, 1H), 4.39 (s, 2H), 4.97 (s, 2H), 6.20 (s, 1H), 7.28–7.34 (m, 5H); 13C NMR (125 MHz, CDCl3): δ 14.0, 21.9, 25.8, 44.1, 59.1, 63.7, 70.9, 78.8, 89.8, 91.6, 115.0, 121.2, 127.4 (2C), 128.1, 128.6 (2C), 136.1, 155.6, 157.9, 161.9, 201.4; HRESIMS m/z 393.1676 [M + Na]+ (calcd for C22H26O5Na, 393.1672). 1-(6-(Benzyloxy)-4-methoxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)-ethan-1-one (11b) Compound 11b was prepared from 10b using the same procedure as for 11a, and was obtained in 86% yield as a colorless oil: IR (neat) νmax 30 64, 2977, 2938, 2872, 1696, 1608, 1474, 1454, 1416, 1384, 1350, 1305, 1271, 1226, 1177, 1162, 1106, 1063, 996, 945, 871, 812, 739, 698 cm–1; 1H NMR (600 MHz, CDCl3): δ 1.13 (s, 3H), 1.31 (d, J = 6.6 Hz, 3H), 1.37 (s, 3H), 2.50 (s, 3H), 3.75 (s, 3H), 4.32 (q, J = 6.6 Hz, 1H), 4.99 (s, 2H), 6.19 (s, 1H), 7.28–7.35 (m, 5H); 13C NMR (150 MHz, CDCl3): δ 14.0, 21.9, 25.7, 32.7, 44.1, 63.1, 70.8, 89.7, 91.5, 118.3, 121.0, 127.2 (2C), 128.0, 128.6 (2C), 136.3, 155.4, 157.5, 161.3, 202.3; HRESIMS m/z 341.1752 [M + H]+ (calcd for C21H25O4, 341.1753). 1-(6-Hydroxy-4-methoxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)-2-methoxyethan-1-one (12a) To a mixture of 11a (2.03 g, 5.49 mmol) in EtOAc (40 mL) was added 10% Pd/C (200 mg) under hydrogen atmosphere (balloon), and the reaction mixture was stirred at rt for 4 h. After the reaction was completed (by TLC check), the reaction mixture was then filtered through Celite and the filtrate was concentrated. The residue was purified by column chromatography eluting with 5% EtOAc in n-hexane to give 12a (1.36 g, 88%) as a colorless oil: IR (neat) νmax 3227, 2980, 2938, 2826, 1710, 1628, 1455, 1408, 1260, 1220, 1160, 1159, 1121, 1094, 1065, 1035, 953, 857, 835, 727 cm–1; 1H NMR (500 MHz, CDCI3): δ 1.18 (s, 3H), 1.32 (d, J = 6.5, 3H), 1.40 (s, 3H), 3.47 (s, 3H), 3.79 (s, 3H), 4.35 (q, J = 6.5 Hz, 1H), 4.63 (s, 2H), 6.16 (s, 1H), 12.9 (s, OH); 13C NMR (125 MHz, CDCI3): δ 14.0, 22.2, 25.7, 43.9, 59.4, 64.6, 76.7, 90.3, 95.9, 108.1, 121.3, 159.3, 166.4, 166.6, 200.3; HRESIMS m/z 303.1201 [M + Na]+ (calcd for C15H20O5Na, 303.1203). 1-(6-Hydroxy-4-methoxy-2,3,3-trimethyl-2,3-dihydrobenzofuran-5-yl)­ethan-1-one (12b) Compound 12b was prepared from 11b using the same procedure as for 12a, and was obtained in 94% yield as a white solid: mp 75–76 °C; IR (KBr) νmax 3481, 2974, 2932, 1621, 1470, 1413, 1324, 1264, 1095, 1060, 949, 845, 723, 671 cm–1; 1H NMR (600 MHz, CDCl3): δ 1.17 (s, 3H), 1.32 (d, J = 6.6 Hz, 3H), 1.40 (s, 3H), 2.64 (s, 3H), 3.78 (s, 3H), 4.35 (q, J = 6.6 Hz, 1H), 6.12 (s, 1H), 13.2 (s, OH); 13C NMR (150 MHz, CDCl3): δ 14.1, 22.2, 25.7, 29.7, 43.9, 90.2, 95.3, 109.7, 121.2, 159.7, 165.9, 166.5, 202.3; HRESIMS m/z 251.1281 [M + H]+ (calcd for C14H19O4, 251.1283). 5-Hydroxy-2-(4-hydroxyphenyl)-3-methoxy-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]­chromen-4-one (17a) To a mixture of 10a (0.72 g, 2.0 mmol) in dry THF (20 mL) at −78 °C under N2 was added 1.0 M LiHMDS (8.0 mL), and the reaction mixture was stirred at −78 °C for 1 h. The reaction mixture was then heated to −10 °C, and stirred tor 1 h. After the reaction mixture was cooled again to −78 °C, 15a (0.80 g, 2.3 mmol) in THF (5 mL) was added and stirred for 1 h. The reaction mixture was gradually warmed to rt and stirred for an additional 24 h. The reaction mixture was quenched slowly with 1 N HCl at 0 °C, and the mixture was extracted with EtOAc three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The crude product 16a was used directly for the next step without further purification. To a mixture of 16a in glacial acetic acid (10 mL) at rt was added concentrated H2SO4 (four drops), and the reaction mixture was heated and stirred at 100 °C (oil bath) for 1 h. After cooling, the reaction mixture was concentrated to remove excess AcOH under high vacuo. The residue was purified by column chromatography eluting with 20% acetone in n-hexane to give 17a (0.29 g, 26%) as a yellow solid: mp 157–158 °C; IR (KBr) νmax 3027, 2982, 2940, 2861, 1650, 1584, 1450, 1425, 1317, 1265, 1159, 1139, 743, 699 cm–1; 1H NMR (600 MHz, CDCl3): δ 1.24 (s, 3H), 1.38 (d, J = 6.6 Hz, 3H), 1.49 (s, 3H), 3.68 (s, 3H), 4.48 (q, J = 6.6 Hz, 1H), 5.23 (s, 2H), 5.26 (s, 2H), 6.23 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 7.28–7.47 (m, 10H), 7.61 (dd, J = 8.4, 2.4 Hz, 1H), 7.74 (d, J = 2.4 Hz, 1H), 12.9 (s, OH); 13C NMR (150 MHz, CDCl3): δ 14.2, 21.6, 26.0, 43.6, 60.1, 70.9, 71.0, 90.5, 94.5, 106.0, 112.5, 113.8, 114.7, 122.2, 123.6, 127.09 (2C), 127.14 (2C), 127.9, 128.1, 128.6 (2C), 128.7 (2C), 136.6, 136.8, 138.8, 148.4, 151.2, 152.0, 154.9, 162.8, 164.9, 178.9; HRESIMS m/z 565.2216 [M + H]+ (calcd for C35H33O7, 565.2221). 2-(4-(Benzyloxy)­phenyl)-5-hydroxy-3-methoxy-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]­chromen-4-one (17b) Compound 17b was prepared from 10a and 15b using the same procedure as for 17a, and was obtained in 26% yield as a white solid: mp 174–175 °C; IR (KBr) νmax 2974, 2935, 1647, 1609, 1583, 1508, 1477, 1399, 1305, 1251, 1212, 1179, 1151, 1003, 870, 833, 822, 749 cm–1; 1H NMR (600 MHz, CDCl3): δ 1.27 (s, 3H), 1.39 (d, J = 6.6 Hz, 3H), 1.53 (s, 3H), 3.83 (s, 3H), 4.50 (q, J = 6.6 Hz, 1H), 5.15 (s, 2H), 6.24 (s, 1H), 7.10 (d, J = 9.0 Hz, 2H), 7.11–7.45 (m, 5H), 8.01 (d, J = 9.0 Hz, 2H), 12.9 (s, OH); 13C NMR (150 MHz, CDCl3): δ 14.2, 21.7, 26.0, 43.6, 60.2, 70.2, 90.5, 94.5, 106.0, 112.5, 115.0 (2C), 123.3, 127.5 (2C), 128.3, 128.7 (2C), 130.0 (2C), 136.3, 138.7, 152.1, 155.2, 160.8, 162.8, 164.9, 178.9; HRESIMS m/z 459.1801 [M + H]+ (calcd for C28H27O6, 459.1802). 2-(3,4-Dihydroxyphenyl)-5-hydroxy-3-methoxy-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]­chromen-4-one (18) To a mixture of 17a (62 mg, 0.11 mmol) in THF/MeOH (1:1, 10 mL) was added 10% Pd/C (20 mg), and the reaction mixture was stirred at rt under hydrogen atmosphere for 2 h. The reaction mixture was then filtered through Celite and the filtrate was concentrated. The residue was purified by column chromatography eluting with 25% acetone in hexane to give 18 (37 mg, 88%) as a yellow solid: mp 261–262 °C; IR (KBr) νmax 3424, 2930, 1658, 1601, 1524, 1458, 1267, 1286, 1218, 1166, 1057, 869, 823 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.30 (s, 3H), 1.39 (d, J = 6.6 Hz, 3H), 1.56 (s, 3H), 3.84 (s, 3H), 4.55 (q, J = 6.6 Hz, 1H), 6.16 (s, 1H), 7.02 (d, J = 8.4 Hz, 1H), 7.56 (dd, J = 8.4, 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 13.1 (s, OH); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 21.8, 26.2, 44.3, 60.2, 91.4, 94.6, 106.5, 113.5, 116.1, 116.3, 121.9, 123.0, 139.1, 146.0, 149.2, 152.9, 156.6, 163.7, 165.8, 179.7; HRESIMS m/z 383.1130 [M – H]− (calcd C21H19O7, 383.1125). 5-Hydroxy-2-(4-hydroxyphenyl)-3-methoxy-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]­chromen-4-one (1) Compound 1 was prepared from 17b using the same procedure as for 18, and was obtained in 92% yield as a yellow solid: mp 229–231 °C (natural ugonin C: mp 236–237 °C);2 IR (KBr) νmax 3284, 2968, 1654, 1608, 1563, 1500, 1450, 1273, 1216, 1166, 1096, 1058, 999, 945, 841, 639 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.30 (s, 3H), 1.39 (d, J = 6.6 Hz, 3H), 1.56 (s, 3H), 3.85 (s, 3H), 4.55 (q, J = 6.6 Hz, 1H), 6.17 (s, 1H), 7.05 (d, J = 9.0 Hz, 2H), 8.00 (d, J = 9.0 Hz, 2H), 13.1 (s, OH); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 21.8, 26.2, 44.4, 60.3, 91.4, 94.5, 106.5, 113.5, 116.5 (2C), 122.5, 131.0 (2C), 139.0, 152.9, 156.7, 161.1, 163.7, 165.8, 179.7; HRESIMS m/z 367.1196 [M – H]− (calcd C21H19O6, 367.1176). 2-(3,4-Dihydroxyphenyl)-3,5-dihydroxy-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]­chromen-4-one (19) To a mixture of 18 (40 mg, 0.10 mmol) in dry CH2Cl2 (20 mL) at 0 °C was added 1.0 M BBr3 in CH2Cl2 (0.52 mL) and the reaction mixture was stirred at rt for 24 h. The reaction mixture was added MeOH to quench the reaction and concentrated. The residue was chromatographed on silica gel eluting with 25% acetone in hexane to give 19 (15 mg, 40%) as a yellow solid: mp 262–264 °C; IR (KBr) νmax 3535, 3336, 2966, 2930, 2886, 1708, 1647, 1606, 1562, 1486, 1392, 1364, 1329, 1272, 1219, 1184, 1158, 1131, 1101, 1054, 1000, 964, 869, 801, 645 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.32 (s, 3H), 1.40 (d, J = 6.6 Hz, 3H), 1.59 (s, 3H), 4.52 (q, J = 6.6 Hz, 1H), 6.15 (s, 1H), 6.89 (d, J = 8.4 Hz, 1H), 7.61 (dd, J = 8.4, 1.8 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H); 13C NMR (150 MHz, CD3OD): δ 14.5, 21.8, 26.5, 44.8, 92.0, 94.6, 105.3, 113.9, 116.0, 116.3, 121.5, 124.2, 137.2, 146.4, 147.8, 148.9, 153.3, 163.1, 166.2, 177.6; HRESIMS m/z 369.0983 [M – H]− (calcd C20H17O7, 369.0969). 3,5-Dihydroxy-2-(4-hydroxyphenyl)-8,9,9-trimethyl-8,9-dihydro-4H-furo- [2,3-h]­Chromen-4-one (2) Compound 2 was prepared from 1 using the same procedure as for 19, and was obtained in 52% yield as a yellow solid: mp 209–211 °C; IR (KBr) νmax 3448, 3343, 2979, 2360, 1648, 1611, 1566, 1484, 1389, 1359, 1327, 1301, 1209, 1177, 1134, 982, 864, 830, 803 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.33 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H), 1.61 (s, 3H), 4.57 (q, J = 6.6 Hz, 1H), 6.19 (s, 1H), 7.05 (d, J = 9.0 Hz, 2H), 8.14 (d, J = 9.0 Hz, 2H), 12.5 (s, OH); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 21.7, 26.2, 44.4, 91.4, 94.4, 104.8, 113.6, 116.5 (2C), 123.4, 130.3 (2C), 136.5, 146.8, 152.9, 160.2, 162.9, 165.9, 176.8; HRESIMS m/z 353.1019 [M – H]− (calcd C20H17O6, 353.1020). 7-(3,4-Dihydroxyphenyl)-4-methoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo-[3,2-g]­chromen-5-one (21a) To a mixture of 12b (0.50 g, 2.0 mmol) in dry THF (15 mL) at −78 °C under N2 was added 1.0 M LiHMDS (6.0 mL), and the reaction mixture was stirred at −10 °C for 1 h. After the reaction mixture was cooled again to −78 °C, 15c (0.79 g, 2.0 mmol) in THF (5 mL) was added. The reaction mixture was gradually warmed to rt and stirred for an additional 24 h. The reaction mixture was quenched slowly with 1 N HCl at 0 °C, and the mixture was extracted with EtOAc three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The crude product 20a was used directly for the next step without further purification. To a mixture of 20a in AcOH (10 mL) was added conc. H2SO4 (four drops) at rt, and the reaction mixture was stirred at 100 °C (oil bath) for 1 h. After cooling, the reaction mixture was quenched with water, slowly adjusted to pH 6 with saturated aqueous Na2CO3 at 0 °C, and the mixture was extracted with EtOAc three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The residue was then dissolved in THF (15 mL) and added 1.0 M TBAF in THF (2.0 mL). The reaction mixture was stirred at rt for 2 h. The reaction mixture was quenched with H2O, and extracted with EtOAc three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography eluting with 30% acetone in n-hexane to give 21a (0.27 g, 37%) as a yellow solid: mp 252–253 °C; IR (KBr) νmax 3476, 2974, 1636, 1518, 1448, 1383, 1250, 1204, 1169, 1115, 1059, 1034, 1019, 980, 956 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.23 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.48 (s, 3H), 3.92 (s, 3H), 4.48 (q, J = 6.6 Hz, 1H), 6.50 (s, 1H), 6.72 (s, 1H), 6.88 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.4, 2.4 Hz, 1H); 13C NMR (150 MHz, CD3OD): δ 14.4, 22.4, 26.2, 45.4, 63.8, 91.8, 95.7, 106.3, 113.1, 113.9, 116.7, 120.0, 123.5, 128.8, 147.0, 150.6, 157.8, 161.1, 164.0, 165.5, 179.5; HRESIMS m/z 367.1194 [M – H]− (calcd C21H19O6, 367.1191). 7-(4-Hydroxyphenyl)-4-methoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]-chromen-5-one (21b) Compound 21b was prepared from 12b and 15d using the same procedure as for 21a, and was obtained in 34% yield as a yellow solid: mp 223–225 °C; IR (KBr) νmax 3476, 2974, 1636, 1518, 1448, 1383, 1250, 1204, 1169, 1115, 1059, 1034, 1019, 980, 956 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.22 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.47 (s, 3H), 3.94 (s, 3H), 4.49 (q, J = 6.6 Hz, 1H), 6.49 (s, 1H), 6.74 (s, 1H), 6.99 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.4 Hz, 2H); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 22.2, 26.0, 44.9, 63.2, 91.0, 95.2, 106.9, 113.4, 116.7 (2C), 123.5, 127.5, 128.7 (2C), 157.7, 160.4, 161.2, 161.6, 164.1, 176.6; HRESIMS m/z 353.1382 [M + H]+ (calcd C21H21O5, 353.1384). 7-(3,4-Dihydroxyphenyl)-4-hydroxy-2,3,3-trimethyl-2,3-dihydro-5H-furo-[3,2-g]­chromen-5-one (3) Compound 3 was prepared from 21a with 1.4 eq. BBr3 (1.0 M in CH2Cl2) at rt for 1 h using the same procedure as for 19, and was obtained in 36% yield as a yellow solid: mp 258–260 °C (natural ugonin T: mp 202–204 °C);4 IR (KBr) νmax 3510, 3101, 2962, 1659, 1625, 1481, 1448, 1375, 1241, 1159, 1055, 813, 578 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.23 (s, 3H), 1.38 (d, J = 6.6 Hz, 3H), 1.47 (s, 3H), 4.50 (q, J = 6.6 Hz, 1H), 6.43 (s, 1H), 6.54 (s, 1H), 6.89 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.37 (dd, J = 8.4, 2.4 Hz, 1H); 13C NMR (150 MHz, CD3OD): δ 14.6, 20.9, 25.5, 44.5, 90.4, 92.2, 103.9, 106.6, 114.1, 116.8, 119.3, 120.3, 123.6, 147.1, 151.0, 158.2, 159.3, 166.3, 166.5, 184.3; HRESIMS m/z 353.1022 [M – H]‑ (calcd C20H17O6, 353.1020). 4-Hydroxy-7-(4-hydroxyphenyl)-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]-chromen-5-one (22) Compound 22 was prepared from 21b using the same procedure as for 3, and was obtained in 59% yield as a yellow solid: mp 263–265 °C; IR (KBr) νmax 3118, 2974, 2816, 1665, 1611, 1553, 1479, 1366, 1247, 1056, 840, 620 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.24 (s, 3H), 1.38 (d, J = 6.6 Hz, 3H), 1.48 (s, 3H), 4.50 (q, J = 6.6 Hz, 1H), 6.47 (s, 1H), 6.60 (s, 1H), 6.92 (d, J = 9.0 Hz, 2H), 7.85 (d, J = 9.0 Hz, 2H); 13C NMR (150 MHz, CD3OD): δ 14.6, 20.9, 25.5, 44.5, 90.5, 92.2, 103.8, 106.6, 117.1 (2C), 119.3, 123.1, 129.5 (2C), 158.2, 159.4, 162.9, 166.2, 166.6, 184.4; HRESIMS m/z 339.1226 [M + H]+ (calcd for C20H19O5, 339.1227). 2-(3,4-Dihydroxyphenyl)-5-hydroxy-8,9,9-trimethyl-8,9-dihydro-4H-furo-[2,3-h]­chromen-4-one (23a) Compound 23a was prepared from 10b and 15c using the same procedure as for 3, and was obtained in 36% yield as a yellow solid: mp 251–252 °C; IR (KBr) νmax 3470, 3101, 2966, 1661, 1601, 1579, 1475, 1444, 1314, 1272, 1238, 1163, 1066, 1008, 969, 845 cm–1; 1H NMR (500 MHz, CD3OD): δ 1.34 (s, 3H), 1.41 (d, J = 6.5 Hz, 3H), 1.61 (s, 3H), 4.55 (q, J = 6.5 Hz, 1H), 6.18 (s, 1H), 6.54 (s, 1H), 6.92 (d, J = 8.0 Hz, 1H), 7.37 (dd, J = 8.0, 2.5 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H); 13C NMR (125 MHz, CD3OD): δ 14.5, 21.9, 26.5, 44.9, 92.1, 95.4, 104.2, 106.1, 114.1, 114.5, 116.9, 120.2, 123.8, 147.2, 151.1, 154.4, 163.8, 166.1, 166.7, 183.9; HRESIMS m/z 353.1036 [M – H]− (calcd for C20H17O6, 353.1020). 5-Hydroxy-2-(4-hydroxyphenyl)-8,9,9-trimethyl-8,9-dihydro-4H-furo­[2,3-h]-chromen-4-one (23b) Compound 23b was prepared from 10b and 15d using the same procedure as for 3, and was obtained in 59% yield as a yellow solid: mp 278–280 °C; IR (KBr) νmax 3154, 2982, 2960, 1653, 1617, 1481, 1400, 1349, 1287, 1218, 1160, 1082, 992, 870, 834, 774, 730, 667 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.33 (s, 3H), 1.41 (d, J = 6.6 Hz, 3H), 1.60 (s, 3H), 4.56 (q, J = 6.6 Hz, 1H), 6.19 (s, 1H), 6.60 (s, 1H), 6.95 (d, J = 9.0 Hz, 2H), 7.84 (d, J = 9.0 Hz, 2H); 13C NMR (150 MHz, CD3OD): δ 14.5, 21.9, 26.5, 44.9, 92.0, 95.4, 104.2, 106.1, 114.5, 117.2 (2C), 123.4, 129.4 (2C), 154.4, 162.9, 163.9, 166.0, 166.7, 184.0; HRESIMS m/z 337.1085 [M – H]− (calcd for C20H17O6, 337.1070). 4-Methoxy-5-(2-methoxyacetyl)-2,3,3-trimethyl-2,3-dihydrobenzofuran-6-yl 3,4-Bis­(benzyloxy)­benzoate (24a) To a mixture of 12a (0.56 g, 2.0 mmol) in CH2Cl2 (20 mL) under N2 was added 13a (0.87 g, 2.6 mmol), DMAP (98 mg, 0.8 mmol), and EDCI (1.73 g, 9.0 mmol) in portion and stirred at rt for 4 h. The reaction mixture was added aq. NH4Cl and extracted with CH2Cl2 three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography eluting with 15% EtOAc in n-hexane to give 24a (1.10 g, 92%) as a colorless oil: IR (neat) νmax 3064, 3032, 2979, 2933, 2826, 1732, 1601, 1512, 1454, 1427, 1385, 1271, 1195, 1144, 1131, 1092, 1061, 1021, 919, 870, 754, 697 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.19 (s, 3H), 1.34 (d, J = 6.5 Hz, 3H), 1.42 (s, 3H), 3.31 (s, 3H), 3.77 (s, 3H), 4.38 (s, 2H), 4.41 (q, J = 6.5 Hz, 1H), 5.18 (s, 2H), 5.22 (s, 2H), 6.41 (s, 1H), 6.94 (d, J = 8.5 Hz, 1H), 7.27–7.46 (m, 10H), 7.67 (d, J = 2.0 Hz, 1H), 7.69 (dd, J = 8.5, 2.0 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 14.0, 21.9, 25.6, 44.3, 59.2, 63.9, 70.8, 71.2, 77.9, 90.0, 101.5, 113.3, 115.8, 118.5, 121.5, 124.9, 126.5, 127.1 (2C), 127.4 (2C), 127.9, 128.0, 128.5 (2C), 128.6 (2C), 136.3, 136.7, 148.4, 149.2, 153.6, 155.7, 161.6, 164.3, 199.7; HRESIMS m/z 619.2295 [M + Na]+ (calcd C36H36O8Na, 619.2302). 4-Methoxy-5-(2-methoxyacetyl)-2,3,3-trimethyl-2,3-dihydrobenzofuran-6-yl 4-(Benzyloxy)­benzoate (24b) Compound 24b was prepared from 12a and 13b using the same procedure as for 24a, and was obtained in 85% yield as a white solid: mp 94–95 °C; IR (KBr) νmax 3099, 3064, 2965, 2938, 2886, 1736, 1709, 1603, 1509, 1455, 1414, 1246 1167, 1148, 1088, 1008, 996, 859, 751, 700 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.19 (s, 3H), 1.34 (d, J = 6.5 Hz, 3H), 1.42 (s, 3H), 3.35 (s, 3H), 3.77 (s, 3H), 4.41 (q, J = 6.5 Hz, 1H), 4.42 (s, 2H), 5.13 (s, 2H), 6.43 (s, 1H), 6.94 (d, J = 9.0 Hz, 2H), 7.31–7.43 (m, 5H), 8.03 (d, J = 9.0 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 14.1, 21.9, 25.6, 44.3, 59.2, 63.9, 70.2, 78.0, 90.0, 101.6, 114.8, 118.6, 121.4, 126.5, 127.5 (2C), 128.3, 128.7 (2C), 132.5, 136.1, 149.2, 155.7, 161.6, 163.2, 164.4, 199.7; HRESIMS m/z 513.1881 [M + Na]+ (calcd C29H30O7Na, 513.1884). 7-(3,4-Bis­(benzyloxy)­phenyl)-4,6-dimethoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (25a) To a mixture of 24a (0.60 g, 1.0 mmol) in dry THF (15 mL) at −20 °C under N2 was added 1.0 M LiHMDS (3.0 mL), and the reaction mixture was stirred at −20 °C for 2 h. The reaction mixture was quenched slowly with 1 N HCl at 0 °C, and the mixture was extracted with EtOAc three times. The combined organic layer was dried over Na2SO4, filtered, and concentrated. The crude product was used directly for the next step without further purification. The crude product was dissolved in AcOH (15.0 mL) and conc. H2SO4 (four drops), and the reaction mixture was heated and stirred at 100 °C (oil bath) for 1 h. After cooling, the reaction mixture was concentrated to remove excess glacial AcOH under high vacuo. The residue was purified by column chromatography eluting with 15% acetone in hexane to give 25a (0.36 g, 62%) as a viscous orange oil: IR (neat) νmax 3064, 2981, 2932, 2871, 1635, 1614, 1511, 1475, 1441, 1362, 1325, 1268, 1215, 1146, 1127, 1099, 1063, 1039, 805, 751, 697 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.22 (s, 3H), 1.36 (d, J = 6.5 Hz, 3H), 1.47 (s, 3H), 3.66 (s, 3H), 3.98 (s, 3H), 4.43 (q, J = 6.5 Hz, 1H), 5.23 (s, 2H), 5.24 (s, 2H), 6.53 (s, 1H), 7.00 (d, J = 8.5 Hz, 1H), 7.28–7.47 (m, 10H), 7.62 (dd, J = 8.5, 2.0 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 14.2, 22.0, 25.7, 44.1, 59.9, 63.2, 70.9, 71.2, 90.4, 94.4, 112.9, 113.8, 114.9, 122.0, 123.7, 126.8, 127.15 (2C), 127.19 (2C), 127.9, 128.0, 128.56 (2C), 128.59 (2C), 136.7, 137.0, 140.7, 148.2, 150.7, 152.7, 156.6, 158.5, 163.4, 173.6; HRESIMS m/z 579.2372 [M + H]+ (calcd C36H35O7, 579.2377). 7-(4-(Benzyloxy)­phenyl)-4,6-dimethoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (25b) Compound 25b was prepared from 24b using the same procedure as for 25a, and was obtained in 62% yield as a viscous orange oil: IR (neat) νmax 2972, 2930, 1619, 1509, 1475, 1440, 1253, 1214, 1182, 1099, 1063, 1036, 835, 738 cm–1; 1H NMR (500 MHz, CDCl3): δ 1.22 (s, 3H), 1.36 (d, J = 6.5 Hz, 3H), 1.47 (s, 3H), 3.81 (s, 3H), 3.99 (s, 3H), 4.43 (q, J = 6.5 Hz, 1H), 5.12 (s, 2H), 6.58 (s, 1H), 7.06 (d, J = 9.0 Hz, 2H), 7.31–7.44 (m, 5H), 8.04 (d, J = 9.0 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 14.1, 21.9, 25.7, 44.1, 59.9, 63.2, 70.0, 90.4, 94.4, 112.9, 114.8 (2C), 123.3, 126.8, 127.4 (2C), 128.1, 128.6 (2C), 129.8 (2C), 136.4, 140.6, 153.0, 156.6, 158.5, 160.4, 163.4, 173.6; HRESIMS m/z 473.1953 [M + H]+ (calcd C29H29O6, 473.1959). 7-(3,4-Dihydroxyphenyl)-4,6-dimethoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (26a) Compound 26a was prepared from 25a using the same procedure as for 18, and was obtained in 91% yield as a yellow solid: mp 134–136 °C; IR (KBr) νmax 3483, 3396, 3103, 2974, 2932, 2748, 1712, 1605, 1521, 1475, 1439, 1368, 1292, 1209, 1168, 1124, 1097, 1061, 1036, 980, 954, 871, 788, 725 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.21 (s, 3H), 1.36 (d, J = 6.6 Hz, 3H), 1.46 (s, 3H), 4.46 (q, J = 6.6 Hz, 1H), 3.80 (s, 3H), 3.95 (s, 3H), 6.66 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 7.53 (dd, J = 8.4, 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 22.2, 26.0, 44.8, 59.7, 63.3, 91.0, 94.9, 113.6, 116.0, 116.1, 121.5, 123.2, 127.3, 141.2, 145.3, 148.5, 153.6, 157.4, 159.4, 164.2, 173.5; HRESIMS m/z 397.1285 [M – H]− (calcd C22H21O7, 397.1282). 7-(4-Hydroxyphenyl)-4,6-dimethoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo-[3,2-g]­chromen-5-one (26b) Compound 26b was prepared from 25b using the same procedure as for 18, and was obtained in 93% yield as a yellow solid: mp 225–226 °C; IR (KBr) νmax 3117, 2972, 2933, 1630, 1598, 1515, 1478, 1447, 1286, 1212, 1180, 1100, 1059, 1037, 956, 849, 820, 650 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.22 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.48 (s, 3H), 3.82 (s, 3H), 3.96 (s, 3H), 4.48 (q, J = 6.6 Hz, 1H), 6.68 (s, 1H), 6.99 (d, J = 9.0 Hz, 2H), 8.00 (d, J = 9.0 Hz, 2H); 13C NMR (150 MHz, acetone-d 6): δ 14.4, 22.2, 26.0, 44.9, 59.7, 63.3, 91.0, 94.9, 113.7, 116.2 (2C), 123.0, 127.3, 130.7 (2C), 141.2, 153.5, 157.5, 159.4, 160.3, 164.2, 173.4; HRESIMS m/z 381.1350 [M – H]− (calcd C22H21O6, 381.1333). 7-(3,4-Dihydroxyphenyl)-4-hydroxy-6-methoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (27a) Compound 27a was prepared from 26a with 1.2 eq. BBr3 (1.0 M in CH2Cl2) at rt for 1 h using the same procedure as for 3, and was obtained in 75% yield as a yellow solid: mp 118–120 °C; IR (KBr) νmax 3461, 3213, 2969, 2937, 1656, 1610, 1557, 1476, 1458, 1367, 1326, 1286, 1209, 1175, 1120, 1097, 1059, 1033, 875, 827 cm–1; 1H NMR (600 MHz, acetone-d 6): δ 1.23 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.47 (s, 3H), 3.85 (s, 3H), 4.51 (q, J = 6.6 Hz, 1H), 6.43 (s, 1H), 6.98 (d, J = 8.4 Hz, 1H), 7.56 (dd, J = 8.4, 2.4 Hz, 1H), 7.69 (d, J = 2.4 Hz, 1H), 13.1 (s, OH); 13C NMR (150 MHz, acetone-d 6): δ 14.5, 20.8, 25.3, 43.9, 60.1, 89.7, 91.5, 106.9, 116.19, 116.22, 118.2, 122.0, 122.9, 139.2, 145.9, 149.1, 156.6, 157.6, 157.9, 165.8179.9; HRESIMS m/z 383.1132 [M – H]− (calcd C21H19O7, 383.1125). 4-Hydroxy-7-(4-hydroxyphenyl)-6-methoxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (27b) Compound 27b was prepared from 26b using the same procedure as for 27a, and was obtained in 91% yield as a yellow solid: mp 156 °C (Sub); IR (KBr) νmax 3422, 3196, 2967, 2938, 1662, 1605, 1548, 1477, 1437, 1364, 1327, 1286, 1221, 1173, 1099, 1057, 1034, 968, 812 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.23 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.48 (s, 3H), 3.77 (s, 3H), 4.49 (q, J = 6.6 Hz, 1H), 6.91 (d, J = 9.0 Hz, 2H), 7.98 (d, J = 9.0 Hz, 2H); 13C NMR (150 MHz, CD3OD): δ 14.6, 20.9, 25.5, 44.5, 60.5, 90.2, 92.2, 107.2, 116.6 (2C), 118.9, 122.5, 131.4 (2C), 139.5, 157.9, 158.0, 158.4, 161.8, 166.6, 180.4; HRESIMS m/z 367.1191 [M – H]− (calcd C21H19O6, 367.1176). 7-(3,4-Dihydroxyphenyl)-4,6-dihydroxy-2,3,3-trimethyl-2,3-dihydro-5H-furo­[3,2-g]­chromen-5-one (4) Compound 4 was prepared from 26a using the same procedure as for 19, and was obtained in 52% yield as a yellow solid: mp 227–229 °C; IR (KBr) νmax 3471, 3336, 2961, 2973, 1660, 1619, 1593, 1512, 1492, 1364, 1323, 1280, 1209, 1159, 1098, 1059, 1027, 955, 808, 785, 750 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.23 (s, 3H), 1.36 (d, J = 6.6 Hz, 3H), 1.47 (s, 3H), 4.47 (q, J = 6.6 Hz, 1H), 6.36 (s, 1H), 6.87 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 1.8 Hz, 1H), 7.72 (dd, J = 8.4, 1.8 Hz, 1H); 13C NMR (150 MHz, CD3OD): δ 14.6, 20.9, 25.5, 44.4, 89.9, 92.1, 105.7, 116.0, 116.2, 118.3, 121.6, 124.1, 137.2, 146.2, 147.9, 148.8, 157.3, 158.1, 166.3, 177.6; HRESIMS m/z 369.0983 [M – H]− (calcd C20H17O7, 369.0969). 4,6-Dihydroxy-7-(4-hydroxyphenyl)-2,3,3-trimethyl-2,3-dihydro-5H-furo-[3,2-g]­chromen-5-one. (28) Compound 28 was prepared from 26b using the same procedure as for 19, and was obtained in 62% yield as a yellow solid: mp 216–217 °C; IR (KBr) νmax 3483, 2957, 2922, 2852, 1655, 1599, 1545, 1488, 1459, 1363, 1276, 1201, 1177, 1162, 1096, 1056, 1027, 836, 805, 749 cm–1; 1H NMR (600 MHz, CD3OD): δ 1.24 (s, 3H), 1.37 (d, J = 6.6 Hz, 3H), 1.48 (s, 3H), 4.48 (q, J = 6.6 Hz, 1H), 6.39 (s, 1H), 6.89 (d, J = 9.0 Hz, 2H), 8.08 (d, J = 9.0 Hz, 2H); 13C NMR (150 MHz, CD3OD): δ 14.6, 20.9, 25.5, 44.4, 90.0, 92.1, 105.8, 116.3 (2C), 118.4, 123.7, 130.7 (2C), 137.2, 148.0, 157.3, 158.2, 160.6, 166.4, 177.7; HRESIMS m/z 353.1036 [M – H]− (calcd C20H17O6, 353.1020). Microglial Cell Culture and Measurements of NO33 The murine microglial cell line (BV2) was cultured in Dulbecco’s modified Eagle medium (Gibco, USA) supplemented with 5% fetal bovine serum (Hyclone). BV-2 cells were pretreated with compound 27a (0.5, 1.0, or 1.5 μM) for 3 h, followed by stimulation with LPS (1 μg/mL) for an additional 4 h. Production of NO was measured by the accumulation of nitrite in the culture medium 24 h after stimulation with LPS by the Griess reagent. Pyrrolidine dithiocarbamate (PDTC), an established inhibitor of NF-κB signaling, was used as a mechanistic positive control to validate NO suppression via the NF-κB/iNOS axis. Data were calculated as 50% inhibitory concentration (EC50) and expressed as the mean ± SEM from 3–5 experiments performed on different days. Measurement of DPPH Radical-Scavenging Capacity DPPH radical-scavenging capacity assay was performed as in our previous report. Briefly, drugs were diluted in MeOH to a range of concentrations (10–50 μM). DPPH solution (200 μL; 200 μM in MeOH) was added to 10 μL of each diluted sample in a 96-well microplate, and the resulting solution was allowed to react for 30 min in the dark at ambient temperature. The absorbance caused by the DPPH radical at 517 nm was determined by a microplate-spectrophotometer. The radical scavenging capacity was expressed as delta OD517 (ΔOD517), and values were the means of three replicates. Trolox, an antioxidant, was included as a reference. Immunofluorescence Staining To evaluate the potential anti-inflammatory activity of compound 27a, an immune-fluorescence labeling assay targeting NF-κB and iNOS was performed. Microglial cells were seeded in 24-well plates at a density of 2.5 × 105 cells/well and treated with LPS (1.0 μg/mL) in the presence or absence of compound 27a (0.5, 1.0, and 1.5 μg/mL) for 3 h. Following treatment, cells were fixed with 4% paraformaldehyde in 0.1 M PBS for 30 min, blocked with 1% BSA in 0.1 M PBS containing 0.1% Triton X-100 for 30 min, and incubated overnight with primary antibodies against phospho-pP65NF-κB (pP65; 1:100) and iNOS (1:400). Nuclei were counterstained with DAPI, and samples were subsequently incubated with fluorochrome-conjugated secondary antibodies. Images were acquired using a Carl Zeiss LSM 780 confocal microscope. Quantitative analysis of colocalization (double positive stain) of pP65 with iNOS was performed by counting 20–30 cells across 3 fields in control and LPS-treated cultures, with or without compound 27a (0.5, 1.0, and 1.5 μg/mL). Each experiment was conducted in duplicate, and the number of double-stained cell of pP65 and iNOS was determined from three randomly selected microscopic fields (400×) per section; the mean value from these fields was used for statistical analysis. Statistical Analysis The mean value ±S.E.M was used to represent all data in the text, tables, and figures. Data analysis was performed using a two-tailed t-test or one-way analysis of variance (ANOVA), followed by the post-hoc Student-Newman-Keuls (S–N–K) t-test for multiple comparisons dose–response relationships were evaluated by linear regression of response levels against drug concentration, and the slope was tested against zero using Student’s t-test. A p-value < 0.05 was considered statistically significant. Supplementary Material